CollPlant Biotechnologies Ltd. Sponsored ADR $CLGN Position Boosted by AMH Equity Ltd

AMH Equity Ltd raised its holdings in shares of CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) by 28.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 160,849 shares of the company’s stock after acquiring an additional 35,849 shares during the quarter. AMH Equity Ltd’s holdings in CollPlant Biotechnologies were worth $219,000 at the end of the most recent quarter.

Separately, Villere ST Denis J & Co. LLC grew its stake in shares of CollPlant Biotechnologies by 13.0% in the 2nd quarter. Villere ST Denis J & Co. LLC now owns 546,867 shares of the company’s stock valued at $744,000 after buying an additional 63,000 shares in the last quarter. Institutional investors own 21.69% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on CLGN. Weiss Ratings reissued a “sell (e+)” rating on shares of CollPlant Biotechnologies in a research note on Wednesday, October 8th. D. Boral Capital reissued a “buy” rating and issued a $12.00 price target on shares of CollPlant Biotechnologies in a research note on Monday, October 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of CollPlant Biotechnologies in a research note on Thursday, August 21st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $11.50.

CollPlant Biotechnologies Stock Down 0.5%

Shares of CollPlant Biotechnologies stock opened at $2.19 on Friday. The stock has a market capitalization of $27.85 million, a P/E ratio of -1.94 and a beta of 1.57. The stock has a 50 day moving average price of $2.52 and a two-hundred day moving average price of $2.22. CollPlant Biotechnologies Ltd. Sponsored ADR has a 12-month low of $1.31 and a 12-month high of $4.98.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its earnings results on Wednesday, August 20th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.57). The company had revenue of $0.18 million for the quarter, compared to the consensus estimate of $8.91 million. CollPlant Biotechnologies had a negative return on equity of 94.08% and a negative net margin of 541.34%. Sell-side analysts anticipate that CollPlant Biotechnologies Ltd. Sponsored ADR will post -1.44 earnings per share for the current year.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.